GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » Cyclically Adjusted PS Ratio

InMed Pharmaceuticals (InMed Pharmaceuticals) Cyclically Adjusted PS Ratio : 0.14 (As of Jun. 09, 2024)


View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-06-09), InMed Pharmaceuticals's current share price is $0.2354. InMed Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.65. InMed Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 0.14.

The historical rank and industry rank for InMed Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

INM' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.14   Med: 0.68   Max: 17.15
Current: 0.14

During the past years, InMed Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 17.15. The lowest was 0.14. And the median was 0.68.

INM's Cyclically Adjusted PS Ratio is ranked better than
96.43% of 504 companies
in the Biotechnology industry
Industry Median: 5.47 vs INM: 0.14

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

InMed Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.122. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.65 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


InMed Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for InMed Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Cyclically Adjusted PS Ratio Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 4.74 0.46

InMed Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.46 0.37 0.24 0.22

Competitive Comparison of InMed Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, InMed Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



InMed Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

InMed Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.2354/1.65
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, InMed Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.122/126.2576*126.2576
=0.122

Current CPI (Mar. 2024) = 126.2576.

InMed Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 99.473 0.000
201409 0.000 99.394 0.000
201412 0.000 98.367 0.000
201503 0.000 99.789 0.000
201506 0.000 100.500 0.000
201509 0.000 100.421 0.000
201512 0.000 99.947 0.000
201603 0.000 101.054 0.000
201606 0.000 102.002 0.000
201609 0.000 101.765 0.000
201612 0.000 101.449 0.000
201703 0.000 102.634 0.000
201706 0.000 103.029 0.000
201709 0.000 103.345 0.000
201712 0.000 103.345 0.000
201803 0.000 105.004 0.000
201806 0.000 105.557 0.000
201809 0.000 105.636 0.000
201812 0.000 105.399 0.000
201903 0.000 106.979 0.000
201906 0.000 107.690 0.000
201909 0.000 107.611 0.000
201912 0.000 107.769 0.000
202003 0.000 107.927 0.000
202006 0.000 108.401 0.000
202009 0.000 108.164 0.000
202012 0.000 108.559 0.000
202103 0.000 110.298 0.000
202106 0.000 111.720 0.000
202109 0.000 112.905 0.000
202112 0.478 113.774 0.530
202203 0.548 117.646 0.588
202206 0.791 120.806 0.827
202209 0.371 120.648 0.388
202212 0.204 120.964 0.213
202303 0.311 122.702 0.320
202306 0.695 124.203 0.706
202309 0.271 125.230 0.273
202312 0.156 125.072 0.157
202403 0.122 126.258 0.122

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


InMed Pharmaceuticals  (NAS:INM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


InMed Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (InMed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Executives
Jonathan Tegge officer: Interim CFO 217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li officer: VP, Accounting and Controller 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric A Adams director, officer: President & CEO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Brenda Edwards officer: Interim CFO 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove director 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill officer: CFO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson officer: SVP & GM of BayMedica LLC 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler director 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu officer: Sr. VP, Pre-Clinical Res/Dev C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Michael Woudenberg officer: VP, Chem/Manufacturing/Control C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Mancini Alexandra Diane Janet officer: Sr VP, Clinical Reg Affairs C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4

InMed Pharmaceuticals (InMed Pharmaceuticals) Headlines